國會辯論旨在應對賽拉嗪威脅的新法案
Congress Debates New Legislation to Combat Xylazine Threats
賽拉嗪，俗稱「喪屍藥」(ㄙㄤˋ尸ㄧㄠˋ)，是一種獸用鎮靜劑，現已成為美國非法藥物市場中一種危險的添加物。
Xylazine, commonly known as "tranq," is a veterinary sedative that has become a dangerous addition to the illicit drug supply in the United States.
由於常與芬太尼混合使用，這種非鴉片類物質引發了嚴重的公共衛生危機，因為納洛酮等標準的逆轉藥物無法抵消其特定的藥效。
Frequently mixed with fentanyl, this non-opioid substance creates a public health crisis because standard reversal medications like naloxone cannot counteract its specific effects.
隨著這種物質在全國蔓延，國會正就兩黨提出的《打擊非法賽拉嗪法案》進行辯論。
As the substance spreads across the country, Congress is debating the bipartisan Combating Illicit Xylazine Act.
該立法旨在將賽拉嗪列為第三級管制藥物，賦予執法人員追蹤其分銷管道並攔截販運者的權力。
This legislation aims to classify xylazine as a Schedule III controlled substance, granting law enforcement the authority to track its distribution and stop traffickers.
農民、牧場主和獸醫依賴賽拉嗪來照護大型動物，因此法案包含了確保他們能持續安全取得該藥物的條款。
Farmers, ranchers, and veterinarians rely on xylazine for large-animal care, so the bill includes provisions to ensure their access remains secure.
支持者希望透過平衡公共安全與專業醫療需求，這項立法將能遏止賽拉嗪從合法供應鏈中被轉用，從而最終解決這項日益嚴重的公共衛生威脅。
By balancing public safety with professional medical needs, supporters hope this legislation will curb the diversion of xylazine from legitimate supply chains, ultimately addressing a growing threat to public health.
